Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 200

1.

PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.

Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, Rampini P, Kossenkov AV, Aird KM, Zhang R, Webster MR, Weeraratna AT, Bosari S, Languino LR, Altieri DC.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8638-43. doi: 10.1073/pnas.1500722112. Epub 2015 Jun 29.

PMID:
26124089
2.

Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression.

Forno I, Ferrero S, Russo MV, Gazzano G, Giangiobbe S, Montanari E, Del Nero A, Rocco B, Albo G, Languino LR, Altieri DC, Vaira V, Bosari S.

PLoS One. 2015 Jun 24;10(6):e0130060. doi: 10.1371/journal.pone.0130060. eCollection 2015.

3.

Corrigendum: Landscape of the mitochondrial Hsp90 metabolome in tumours.

Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, Powers JF, Tischler AS, Pacak K, Fliedner S, Michalek RD, Karoly ED, Wallace DC, Languino LR, Speicher DW, Altieri DC.

Nat Commun. 2015 Jun 18;6:7605. doi: 10.1038/ncomms8605. No abstract available.

PMID:
26085380
4.

Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.

Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, Pestell RG, Altieri DC, Languino LR.

Oncotarget. 2015 Jun 10;6(16):14318-28.

5.

Adaptive mitochondrial reprogramming and resistance to PI3K therapy.

Ghosh JC, Siegelin MD, Vaira V, Faversani A, Tavecchio M, Chae YC, Lisanti S, Rampini P, Giroda M, Caino MC, Seo JH, Kossenkov AV, Michalek RD, Schultz DC, Bosari S, Languino LR, Altieri DC.

J Natl Cancer Inst. 2015 Feb 3;107(3). pii: dju502. doi: 10.1093/jnci/dju502. Print 2015 Mar.

PMID:
25650317
6.

Survivin - The inconvenient IAP.

Altieri DC.

Semin Cell Dev Biol. 2015 Mar;39:91-6. doi: 10.1016/j.semcdb.2014.12.007. Epub 2015 Jan 12. Review.

PMID:
25591986
7.

Deletion of the mitochondrial chaperone TRAP-1 uncovers global reprogramming of metabolic networks.

Lisanti S, Tavecchio M, Chae YC, Liu Q, Brice AK, Thakur ML, Languino LR, Altieri DC.

Cell Rep. 2014 Aug 7;8(3):671-7. doi: 10.1016/j.celrep.2014.06.061. Epub 2014 Jul 31.

8.

microRNA-mediated survivin control of pluripotency.

Kapinas K, Kim H, Mandeville M, Martin-Buley LA, Croce CM, Lian JB, van Wijnen AJ, Stein JL, Altieri DC, Stein GS.

J Cell Physiol. 2015 Jan;230(1):63-70. doi: 10.1002/jcp.24681.

PMID:
24891298
9.

Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.

Faversani A, Vaira V, Moro GP, Tosi D, Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC, Bosari S.

Breast Cancer Res. 2014 May 30;16(3):R55. doi: 10.1186/bcr3666.

10.

Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells.

Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, Weeraratna A, O'Connell M, Jernigan D, Fatatis A, Languino LR, Bosari S, Altieri DC.

J Clin Invest. 2013 Jul;123(7):2907-20. doi: 10.1172/JCI67841. Epub 2013 Jun 10.

11.

Landscape of the mitochondrial Hsp90 metabolome in tumours.

Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, Powers JF, Tischler AS, Pacak K, Fliedner S, Michalek RD, Karoly ED, Wallace DC, Languino LR, Speicher DW, Altieri DC.

Nat Commun. 2013;4:2139. doi: 10.1038/ncomms3139.

12.

Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.

Simon-Keller K, Paschen A, Hombach AA, Ströbel P, Coindre JM, Eichmüller SB, Vincent A, Gattenlöhner S, Hoppe F, Leuschner I, Stegmaier S, Koscielniak E, Leverkus M, Altieri DC, Abken H, Marx A.

Am J Pathol. 2013 Jun;182(6):2121-31. doi: 10.1016/j.ajpath.2013.02.017. Epub 2013 Apr 2.

13.

Regulation of lung cancer metastasis by Klf4-Numb-like signaling.

Vaira V, Faversani A, Martin NM, Garlick DS, Ferrero S, Nosotti M, Kissil JL, Bosari S, Altieri DC.

Cancer Res. 2013 Apr 15;73(8):2695-705. doi: 10.1158/0008-5472.CAN-12-4232. Epub 2013 Feb 25.

14.

β1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1.

Goel HL, Sayeed A, Breen M, Zarif MJ, Garlick DS, Leav I, Davis RJ, Fitzgerald TJ, Morrione A, Hsieh CC, Liu Q, Dicker AP, Altieri DC, Languino LR.

J Cell Physiol. 2013 Jul;228(7):1601-9. doi: 10.1002/jcp.24323.

15.

Cyclophilin D extramitochondrial signaling controls cell cycle progression and chemokine-directed cell motility.

Tavecchio M, Lisanti S, Lam A, Ghosh JC, Martin NM, O'Connell M, Weeraratna AT, Kossenkov AV, Showe LC, Altieri DC.

J Biol Chem. 2013 Feb 22;288(8):5553-61. doi: 10.1074/jbc.M112.433045. Epub 2013 Jan 9.

16.

Mitochondrial HSP90s and tumor cell metabolism.

Altieri DC.

Autophagy. 2013 Feb 1;9(2):244-5. doi: 10.4161/auto.22527. Epub 2012 Oct 29.

17.

Hsp90 regulation of mitochondrial protein folding: from organelle integrity to cellular homeostasis.

Altieri DC.

Cell Mol Life Sci. 2013 Jul;70(14):2463-72. doi: 10.1007/s00018-012-1177-0. Epub 2012 Sep 30.

18.

Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s.

Chae YC, Caino MC, Lisanti S, Ghosh JC, Dohi T, Danial NN, Villanueva J, Ferrero S, Vaira V, Santambrogio L, Bosari S, Languino LR, Herlyn M, Altieri DC.

Cancer Cell. 2012 Sep 11;22(3):331-44. doi: 10.1016/j.ccr.2012.07.015.

19.

Mitochondrial heat shock protein-90 modulates vascular smooth muscle cell survival and the vascular injury response in vivo.

Hoel AW, Yu P, Nguyen KP, Sui X, Plescia J, Altieri DC, Conte MS.

Am J Pathol. 2012 Oct;181(4):1151-7. doi: 10.1016/j.ajpath.2012.06.023. Epub 2012 Jul 27.

20.

α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma.

Garlick DS, Li J, Sansoucy B, Wang T, Griffith L, Fitzgerald T, Butterfield J, Charbonneau B, Violette SM, Weinreb PH, Ratliff TL, Liao CP, Roy-Burman P, Vietri M, Lian JB, Stein GS, Altieri DC, Languino LR.

Am J Transl Res. 2012;4(2):165-74. Epub 2012 Apr 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk